International Agency for Research on Cancer. Colorectal cancer. World Health Organization; 2021. https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf. Accessed 16 Apr 2024.

International Agency for Research on Cancer. Japan fact sheet. The Global Cancer Observatory; 2021. https://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf. Accessed 16 Apr 2024.

Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14: 101174.

Article  PubMed  PubMed Central  Google Scholar 

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.

Article  PubMed  Google Scholar 

Ahiko Y, Shida D, Kudose Y, Nakamura Y, Moritani K, Yamauchi S, et al. Recurrence hazard of rectal cancer compared with colon cancer by adjuvant chemotherapy status: a nationwide study in Japan. J Gastroenterol. 2021;56:371–81.

Article  CAS  PubMed  Google Scholar 

NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Colon cancer. National Comprehensive Cancer Network; 2023. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 16 Apr 2024.

Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.

Article  CAS  PubMed  Google Scholar 

Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, et al. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol. 2015;26:1427–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508.

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.

Article  PubMed  Google Scholar 

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.

Article  CAS  PubMed  Google Scholar 

Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, et al. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci. 2016;107:1843–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.

Article  CAS  PubMed  Google Scholar 

Tabernero J, Van Cutsem E, Lakomy R, Prausova J, Ruff P, van Hazel GA, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50:320–31.

Article  CAS  PubMed  Google Scholar 

Medical database overview (as of the end of March 2023). Number of actual patients: 43.22 million [Japanese]. Medical Data Vision; 2023. https://www.mdv.co.jp/press/2023/detail_1979.html. Accessed 16 Apr 2024.

Cancer Statistics in Japan: 2023. Foundation for promotion of cancer research; 2023. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2023.pdf. Accessed 16 Apr 2024.

Ethical guidelines for medical and health research involving human subjects. Tokyo: Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare; 2018. https://www.lifescience.mext.go.jp/files/pdf/n2181_01.pdf. Accessed 16 Apr 2024.

Cremolini C, Montagut C, Ronga P, Venturini F, Yamaguchi K, Stintzing S, et al. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol. 2022;12: 946850.

Article  CAS  PubMed  Google Scholar 

R Core Team. R: a language and environment for statistical computing, 3.2.1 edn. Vienna: R Foundation for Statistical Computing; 2021.

Sugimoto N, Nakata K, Miyo M, Yoshioka S, Kagawa Y, Naito A, et al. P-76 Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD). Ann Oncol. 2022;33:S274.

Article  Google Scholar 

Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C, et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res. 2014;34:1967–73.

CAS  PubMed  Google Scholar 

Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, et al. Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep. 2017;7:10426.

Article  PubMed  PubMed Central  Google Scholar 

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25:107–16.

Article  CAS  PubMed  Google Scholar 

Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853–60.

Article  CAS  PubMed  Google Scholar 

Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329:1271–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shinozaki E, Makiyama A, Kagawa Y, Satake H, Tanizawa Y, Cai Z, et al. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: a retrospective observational study using an administrative database. PLoS ONE. 2021;16: e0246160.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Itatani Y, Kawada K, Sakai Y. Treatment of elderly patients with colorectal cancer. Biomed Res Int. 2018;2018:2176056.

Article  PubMed  PubMed Central  Google Scholar 

Millan M, Merino S, Caro A, Feliu F, Escuder J, Francesch T. Treatment of colorectal cancer in the elderly. World J Gastrointest Oncol. 2015;7:204–20.

Article  PubMed  PubMed Central  Google Scholar 

McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, et al. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin Colorectal Cancer. 2016;15:135–40.

Article  PubMed  Google Scholar 

Xu R, Wang W, Zhu B, Lin X, Ma D, Zhu L, et al. Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. BMC Cancer. 2020;20:131.

Article  PubMed  PubMed Central  Google Scholar 

Satake H, Kagawa Y, Shinozaki E, Tanizawa Y, Jin L, Cai Z, et al. Real-world data analysis of second-line antiangiogenic targeted treatments following anti-epidermal growth factor receptor monoclonal antibodies and first-line FOLFOX for patients with metastatic colorectal cancer. Adv Ther. 2022;39:2596–613.

Article  PubMed  PubMed Central  Google Scholar 

Parikh RC, Du XL, Morgan RO, Lairson DR. Patterns of treatment sequences in chemotherapy and targeted biologics for metastatic colorectal cancer: findings from a large community-based cohort of elderly patients. Drugs Real World Outcomes. 2016;3:69–82.

Article  PubMed  PubMed Central  Google Scholar 

Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 2013;24:186–92.

Article  CAS  PubMed  Google Scholar